Nikolaus Sarafoff

Summary

Publications

  1. doi Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation
    Nikolaus Sarafoff
    Klinikum der Ludwig Maximilians Universität München, Medizinische Klinik und Poliklinik I, Munich, Germany
    J Am Coll Cardiol 61:2060-6. 2013
  2. doi Association of ST-elevation and non-ST-elevation presentation on ECG with transmurality and size of myocardial infarction as assessed by contrast-enhanced magnetic resonance imaging
    Nikolaus Sarafoff
    Klinik für Herz und Kreislauferkrankungen, Deutsches Herzzentrum, Technical University Munich, Germany
    J Electrocardiol 46:100-6. 2013
  3. ncbi Clinical use of clopidogrel
    Nikolaus Sarafoff
    Deutsches Herzzentrum, Technische Universität Munich, Germany
    Curr Pharm Des 18:5224-39. 2012
  4. doi Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting
    Nikolaus Sarafoff
    Deutsches Herzzentrum Munchen, Munich, Germany
    Am Heart J 161:605-10. 2011
  5. doi Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-
    K Anette Fiedler
    Deutsches Herzzentrum, Technische Universitat, Munich, Germany DZHK German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Munich, Germany Electronic address
    Am Heart J 167:459-465.e1. 2014
  6. doi Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Lazarettstrasse, Munich, Germany
    Eur Heart J 31:1205-11. 2010
  7. doi Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors
    Nikolaus Sarafoff
    Deutsches Herzzentrum Munchen, Klinik für Herz und Kreislauferkrankungen Lazarettstr 3680636 Munich, Germany
    Thromb Haemost 104:626-32. 2010
  8. doi Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial
    Katrin A Fiedler
    Deutsches Herzzentrum Munchen, Technische Universitat, Klinik für Herz und Kreislauferkrankungen, Munich, Germany
    J Am Coll Cardiol 65:1619-29. 2015
  9. doi Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment
    Robert A Byrne
    Deutsches Herzzentrum, Technische Universitat, Munich, Germany
    Drug Saf 32:749-70. 2009

Collaborators

Detail Information

Publications9

  1. doi Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation
    Nikolaus Sarafoff
    Klinikum der Ludwig Maximilians Universität München, Medizinische Klinik und Poliklinik I, Munich, Germany
    J Am Coll Cardiol 61:2060-6. 2013
    ..This study sought to evaluate whether prasugrel may serve as an alternative to clopidogrel in patients with triple therapy...
  2. doi Association of ST-elevation and non-ST-elevation presentation on ECG with transmurality and size of myocardial infarction as assessed by contrast-enhanced magnetic resonance imaging
    Nikolaus Sarafoff
    Klinik für Herz und Kreislauferkrankungen, Deutsches Herzzentrum, Technical University Munich, Germany
    J Electrocardiol 46:100-6. 2013
    ..This association, however, derives primarily from post mortem studies...
  3. ncbi Clinical use of clopidogrel
    Nikolaus Sarafoff
    Deutsches Herzzentrum, Technische Universität Munich, Germany
    Curr Pharm Des 18:5224-39. 2012
    ....
  4. doi Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting
    Nikolaus Sarafoff
    Deutsches Herzzentrum Munchen, Munich, Germany
    Am Heart J 161:605-10. 2011
    ..The aim of this study was to assess the impact of CCB therapy on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stent placement...
  5. doi Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-
    K Anette Fiedler
    Deutsches Herzzentrum, Technische Universitat, Munich, Germany DZHK German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Munich, Germany Electronic address
    Am Heart J 167:459-465.e1. 2014
    ....
  6. doi Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel
    Dirk Sibbing
    Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Lazarettstrasse, Munich, Germany
    Eur Heart J 31:1205-11. 2010
    ..The aim of this study was to investigate the impact of phenprocoumon on the antiplatelet effects of clopidogrel in patients with coronary artery disease...
  7. doi Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors
    Nikolaus Sarafoff
    Deutsches Herzzentrum Munchen, Klinik für Herz und Kreislauferkrankungen Lazarettstr 3680636 Munich, Germany
    Thromb Haemost 104:626-32. 2010
    ..The higher mortality is probably due to confounding as patients on PPIs had a higher risk profile at baseline...
  8. doi Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial
    Katrin A Fiedler
    Deutsches Herzzentrum Munchen, Technische Universitat, Klinik für Herz und Kreislauferkrankungen, Munich, Germany
    J Am Coll Cardiol 65:1619-29. 2015
    ..Such triple therapy confers an elevated bleeding risk, and its optimal duration is not known...
  9. doi Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment
    Robert A Byrne
    Deutsches Herzzentrum, Technische Universitat, Munich, Germany
    Drug Saf 32:749-70. 2009
    ..On the balance of benefit and risk data available, DES implantation should be the preferred approach across the spectrum of patients with obstructive coronary disease who require PCI therapy...